TuHURA Biosciences, Inc.
HURA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$122.99M
Close$
$0.06
96.8% downside
Current Fair Value
96.8% downsideOvervalued by 96.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $122.99 Million |
|---|---|
| Enterprise Value | $117.15 Million |
| Earnings per Share | $-0.63 |
| Beta | -0.01 |
| Outstanding Shares | 63,963,513 |
Return
| Return on Equity | -144.00% |
|---|---|
| Return on Assets | -112.42% |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.57 |
|---|---|
| PEG | 113.29 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.14
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.31%▼ 13.73% |
|---|---|
| Total Invested | $412,529▼ 98.04% |
| Investors Holding | 4▼ 85.00% |
About Kintara Therapeutics Inc
22 employees
CEO: Saiid Zarrabian
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mecha...